Direct To Patient was Myomo’s largest revenue line in fiscal 2024, bringing in $25.33M of $32.55M (78%).
| Customer | FY 2019 | FY 2020 | FY 2021 | FY 2024 |
|---|---|---|---|---|
| Direct To Patient | $10.67M | $25.33M | ||
| Clinical/Medical Providers | $3.19M | $7.22M | ||
| Total | $13.86M | $32.55M |
Myomo brought in $32.55M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. That was up 134.9% from $13.86M in fiscal 2021, the previous year with figures. Direct To Patient was the largest at $25.33M (77.8%), ahead of Clinical/Medical Providers at $7.22M (22.2%).
Compared with fiscal 2021, the previous year with figures, Direct To Patient grew 137.4% to $25.33M and Clinical/Medical Providers grew 126.7% to $7.22M. From fiscal 2021 to 2024, combined revenue from these revenue lines grew from $13.86M to $32.55M, a compound annual growth rate of 32.9%. Direct To Patient's share of the total rose from 77.0% to 77.8%.
Myomo (MYO) reports its revenue by customer. In fiscal 2024, Direct To Patient was its largest revenue line, bringing in $25.33M (77.8% of the total), followed by Clinical/Medical Providers at $7.22M (22.2%).
Direct To Patient was Myomo's largest revenue line in fiscal 2024, bringing in $25.33M, or 77.8% of the $32.55M total across its two revenue lines.
Every figure comes from Myomo's annual financial filings, as reported. Each line keeps the name Myomo gives it, and years follow its fiscal calendar.
Myomo's revenue by customer goes back to fiscal 2019, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.